XBRANE BIOPHARMA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.298 SEK | +15.95% |
|
+21.63% | -97.02% |
| 05-22 | Xbrane Successfully Scale Up Xdivane- Biosimilar Candidate to Opdivo®? | CI |
| 05-16 | Transcript : Xbrane Biopharma AB, Q1 2024 Earnings Call, May 16, 2024 |
Presenter SpeechMartin Åmark (Executives)Hello, everybody. And welcome to our webcast in relat...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Xbrane Biopharma AB, formerly Xbrane Bioscience AB, is a Sweden-based provider of biotechnology research and development services. It develops biogenerics for injectable slow release drugs and high-yield protein expression technology for the development of biosimilars. The Company's main products are Sperotide, a generic on the originator drug marketed under the trademarks Decapeptyl, Trelstar and Pamorelin, as well as Xlucane, a biosimilar on the originator drug sold under the trademark Lucentis.
Calendar
2024-07-17
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.298
SEK
Average target price
0.6
SEK
Spread / Average Target
+101.34%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -97.02% | 43.27M | |
| +43.36% | 54.64B | |
| -5.31% | 39.92B | |
| +37.52% | 38.82B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +25.12% | 12.21B | |
| +0.04% | 12.16B | |
| +26.04% | 11.94B |
- Stock Market
- Equities
- XBRANE Stock
- News Xbrane Biopharma AB
- Transcript : Xbrane Biopharma AB, Q1 2024 Earnings Call, May 16, 2024
